These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 2790813

  • 1. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
    Teicher BA, Holden SA, Eder JP, Brann TW, Jones SM, Frei E.
    Cancer Res; 1989 Nov 01; 49(21):5994-8. PubMed ID: 2790813
    [Abstract] [Full Text] [Related]

  • 2. Modulation of alkylating agents by etanidazole and Fluosol-DA/carbogen in the FSaIIC fibrosarcoma and EMT6 mammary carcinoma.
    Teicher BA, Herman TS, Tanaka J, Eder JP, Holden SA, Bubley G, Coleman CN, Frei E.
    Cancer Res; 1991 Feb 15; 51(4):1086-91. PubMed ID: 1825474
    [Abstract] [Full Text] [Related]

  • 3. Lonidamine as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA, Herman TS, Holden SA, Epelbaum R, Liu SD, Frei E.
    Cancer Res; 1991 Feb 01; 51(3):780-4. PubMed ID: 1988117
    [Abstract] [Full Text] [Related]

  • 4. Efficacy of pentoxifylline as a modulator of alkylating agent activity in vitro and in vivo.
    Teicher BA, Holden SA, Herman TS, Epelbaum R, Pardee AB, Dezube B.
    Anticancer Res; 1991 Feb 01; 11(4):1555-60. PubMed ID: 1746913
    [Abstract] [Full Text] [Related]

  • 5. Preclinical studies and clinical correlation of the effect of alkylating dose.
    Frei E, Teicher BA, Holden SA, Cathcart KN, Wang YY.
    Cancer Res; 1988 Nov 15; 48(22):6417-23. PubMed ID: 3180059
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
    Teicher BA, Cucchi CA, Lee JB, Flatow JL, Rosowsky A, Frei E.
    Cancer Res; 1986 Sep 15; 46(9):4379-83. PubMed ID: 3731096
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Preclinical studies relating to the use of thiotepa in the high-dose setting alone and in combination.
    Teicher BA, Holden SA, Eder JP, Herman TS, Antman KH, Frei E.
    Semin Oncol; 1990 Feb 15; 17(1 Suppl 3):18-32. PubMed ID: 2106164
    [Abstract] [Full Text] [Related]

  • 11. Evidence for enzymatic activation and oxygen involvement in cytotoxicity and antitumor activity of N,N',N''-triethylenethiophosphoramide.
    Teicher BA, Waxman DJ, Holden SA, Wang YY, Clarke L, Alvarez Sotomayor E, Jones SM, Frei E.
    Cancer Res; 1989 Sep 15; 49(18):4996-5001. PubMed ID: 2504483
    [Abstract] [Full Text] [Related]

  • 12. Effects of RSR13 and oxygen on the cytotoxicity of cisplatin and carboplatin to EMT6 mouse mammary tumor cells in vitro and in vivo.
    Donnelly ET, Kelley M, Rockwell S.
    Cancer Chemother Pharmacol; 2004 Jan 15; 53(1):43-50. PubMed ID: 14574460
    [Abstract] [Full Text] [Related]

  • 13. Influence of scheduling on two-drug combinations of alkylating agents in vivo.
    Teicher BA, Holden SA, Jones SM, Eder JP, Herman TS.
    Cancer Chemother Pharmacol; 1989 Jan 15; 25(3):161-6. PubMed ID: 2513139
    [Abstract] [Full Text] [Related]

  • 14. Cross-resistance and glutathione-S-transferase-pi levels among four human melanoma cell lines selected for alkylating agent resistance.
    Wang YY, Teicher BA, Shea TC, Holden SA, Rosbe KW, al-Achi A, Henner WD.
    Cancer Res; 1989 Nov 15; 49(22):6185-92. PubMed ID: 2804968
    [Abstract] [Full Text] [Related]

  • 15. Effect of novobiocin on the antitumor activity and tumor cell and bone marrow survivals of three alkylating agents.
    Eder JP, Teicher BA, Holden SA, Cathcart KN, Schnipper LE, Frei E.
    Cancer Res; 1989 Feb 01; 49(3):595-8. PubMed ID: 2910481
    [Abstract] [Full Text] [Related]

  • 16. Transforming growth factor-beta 1 overexpression produces drug resistance in vivo: reversal by decorin.
    Teicher BA, Ikebe M, Ara G, Keyes SR, Herbst RS.
    In Vivo; 1997 Feb 01; 11(6):463-72. PubMed ID: 9509296
    [Abstract] [Full Text] [Related]

  • 17. PEG-hemoglobin: effects on tumor oxygenation and response to chemotherapy.
    Teicher BA, Ara G, Herbst R, Takeuchi H, Keyes S, Northey D.
    In Vivo; 1997 Feb 01; 11(4):301-11. PubMed ID: 9292296
    [Abstract] [Full Text] [Related]

  • 18. Modulation of alkylating agents by lonidamine in vivo.
    Teicher BA, Holden SA, Herman TS, Frei E.
    Semin Oncol; 1991 Apr 01; 18(2 Suppl 4):7-10. PubMed ID: 1903216
    [Abstract] [Full Text] [Related]

  • 19. Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.
    Teicher BA, Herman TS, Tanaka J, Dezube B, Pardee A, Frei E.
    Cancer Chemother Pharmacol; 1991 Apr 01; 28(1):45-50. PubMed ID: 1904012
    [Abstract] [Full Text] [Related]

  • 20. Etoposide with lonidamine or pentoxifylline as modulators of alkylating agent activity in vivo.
    Tanaka J, Teicher BA, Herman TS, Holden SA, Dezube B, Frei E.
    Int J Cancer; 1991 Jun 19; 48(4):631-7. PubMed ID: 2045206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.